{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "12203050",
  "DateCompleted": {
    "Year": "2002",
    "Month": "11",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "10",
    "Day": "26"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0300-9564",
      "JournalIssue": {
        "Volume": "109",
        "Issue": "9",
        "PubDate": {
          "Year": "2002",
          "Month": "Sep"
        }
      },
      "Title": "Journal of neural transmission (Vienna, Austria : 1996)",
      "ISOAbbreviation": "J Neural Transm (Vienna)"
    },
    "ArticleTitle": "Effects of U-50,488H, a kappa-opioid receptor agonist, on the learned helplessness model of depression in mice.",
    "Pagination": {
      "StartPage": "1221",
      "EndPage": "1225",
      "MedlinePgn": "1221-5"
    },
    "Abstract": {
      "AbstractText": [
        "We investigated the effects of U-50,488H, a kappa-opioid receptor agonist, on the learned helplessness model of depression in mice. Mice pre-exposed to inescapable electric footshock were treated with U-50,488H. Stimulation of the kappa-opioid receptor by U-50,488H (10 mg/kg/day, i.p.) attenuated the escape failure induced by pre-exposure to shock. This attenuation by U-50,488H was blocked by MR2266 (10 mg/kg/day, s.c.), an opioid receptor antagonist. These results suggest that the kappa-opioid system plays an important role in the learned helplessness depression in mice."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Japan. ukai@ccmfs.meijo-u.ac.jp"
          }
        ],
        "LastName": "Ukai",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Suzuki",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mamiya",
        "ForeName": "T",
        "Initials": "T"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Austria",
    "MedlineTA": "J Neural Transm (Vienna)",
    "NlmUniqueID": "9702341",
    "ISSNLinking": "0300-9564"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Analgesics, Non-Narcotic"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Benzomorphans"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Narcotic Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Opioid Peptides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptors, Opioid, kappa"
    },
    {
      "RegistryNumber": "56649-76-4",
      "NameOfSubstance": "MR 2266"
    },
    {
      "RegistryNumber": "67198-13-4",
      "NameOfSubstance": "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Analgesics, Non-Narcotic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Benzomorphans"
    },
    {
      "QualifierName": [
        "drug effects",
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Brain"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Models, Animal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Helplessness, Learned"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mice"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Narcotic Antagonists"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Opioid Peptides"
    },
    {
      "QualifierName": [
        "agonists",
        "metabolism"
      ],
      "DescriptorName": "Receptors, Opioid, kappa"
    }
  ]
}